U.S. Court Action Could Jeopardize Ranbaxy-Daiichi Merger Plans
This article was originally published in PharmAsia News
U.S. allegations Ranbaxy Laboratories may have adulterated some generic drugs marketed in the United States could trouble the proposed purchase of India's largest drug maker by Japan's Daiichi Sankyo. Drug industry analysts are concerned the nature of the accusations leveled in a motion in U.S. court by the Justice Department could derail the merger plan. Experts believe Ranbaxy already must have informed Daiichi about the investigation, which the Indian company has acknowledged publicly is taking place. A Daiichi spokesperson said the firm was studying legal liabilities involved. (Click here for more
You may also be interested in...
Ranbaxy has denied U.S. FDA allegations that it conducted "systematic fraudulent conduct" related to concealing violations of current good manufacturing practices
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.